Biologics for psoriasis and risk of genital warts
Part of Skin clinical trials.
This study looks at whether biologic medicines for psoriasis affect the risk of developing genital warts. You may join if you have moderate to severe psoriasis and are starting or already on a biologic.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your psoriasis is moderate to severe (either covers more than 10% of your body or has a PASI score over 10).
- You are about to start (or have just started) a biologic medicine for psoriasis.
- You can see your dermatologist as usual for about 2 years.
- You do not have a serious immune system problem (like uncontrolled HIV or taking very strong immune-suppressing drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
This study tests whether adding a Mediterranean diet to your psoriasis treatment can improve your skin. You will be asked to follow a heart-healthy diet for several months while taking a new biologic medicine.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This trial looks at how different biologic treatments work when used one after another for people with plaque psoriasis. It may help find the best order of treatments to keep your skin clear.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.